{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:36:30Z","timestamp":1792726590207,"version":"4.5.0"},"reference-count":175,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1038\/s41571-021-00508-x","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T11:45:02Z","timestamp":1620733502000},"page":"591-602","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Beneficial autoimmunity improves cancer prognosis"],"prefix":"10.1038","volume":"18","author":[{"given":"Laurence","family":"Zitvogel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9453-7383","authenticated-orcid":false,"given":"Claude","family":"Perreault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivera J.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9334-4405","authenticated-orcid":false,"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"key":"508_CR1","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/0140-6736(91)92110-N","volume":"338","author":"G Kroemer","year":"1991","unstructured":"Kroemer, G. & Martinez, C. The fail-safe paradigm of immunological self-tolerance. Lancet 338, 1246\u20131249 (1991).","journal-title":"Lancet"},{"key":"508_CR2","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1146\/annurev-immunol-042617-053411","volume":"36","author":"I Taniuchi","year":"2018","unstructured":"Taniuchi, I. CD4 helper and CD8 cytotoxic T cell differentiation. Annu. Rev. Immunol. 36, 579\u2013601 (2018).","journal-title":"Annu. Rev. Immunol."},{"key":"508_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07825-3","volume":"9","author":"Y Ovadya","year":"2018","unstructured":"Ovadya, Y. et al. Impaired immune surveillance accelerates accumulation of senescent cells and aging. Nat. Commun. 9, 5435 (2018).","journal-title":"Nat. Commun."},{"key":"508_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12979-020-00187-9","volume":"17","author":"A Kale","year":"2020","unstructured":"Kale, A., Sharma, A., Stolzing, A., Desprez, P. Y. & Campisi, J. Role of immune cells in the removal of deleterious senescent cells. Immun. Ageing 17, 16 (2020).","journal-title":"Immun. Ageing"},{"key":"508_CR5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1146\/annurev-pathmechdis-012419-032847","volume":"15","author":"J Zindel","year":"2020","unstructured":"Zindel, J. & Kubes, P. DAMPs, PAMPs, and LAMPs in Immunity and Sterile Inflammation. Annu. Rev. Pathol. 15, 493\u2013518 (2020).","journal-title":"Annu. Rev. Pathol."},{"key":"508_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1071059","volume":"296","author":"P Matzinger","year":"2002","unstructured":"Matzinger, P. The danger model: a renewed sense of self. Science 296, 301\u2013305 (2002).","journal-title":"Science"},{"key":"508_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41577-019-0215-7","volume":"20","author":"T Gong","year":"2020","unstructured":"Gong, T., Liu, L., Jiang, W. & Zhou, R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat. Rev. Immunol. 20, 95\u2013112 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"508_CR8","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960\u20131964 (2006).","journal-title":"Science"},{"key":"508_CR9","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman, W. H., Zitvogel, L., Sautes-Fridman, C. & Kroemer, G. The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14, 717\u2013734 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"508_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41571-020-0333-y","volume":"17","author":"A Byrne","year":"2020","unstructured":"Byrne, A. et al. Tissue-resident memory T cells in breast cancer control and immunotherapy responses. Nat. Rev. Clin. Oncol. 17, 341\u2013348 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"508_CR11","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3389\/fimmu.2018.00470","volume":"9","author":"M Shen","year":"2018","unstructured":"Shen, M., Wang, J. & Ren, X. New insights into tumor-infiltrating b lymphocytes in breast cancer: clinical impacts and regulatory mechanisms. Front. Immunol. 9, 470 (2018).","journal-title":"Front. Immunol."},{"key":"508_CR12","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556\u2013560 (2020).","journal-title":"Nature"},{"key":"508_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"508_CR14","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189\u20132199 (2014).","journal-title":"N. Engl. J. Med."},{"key":"508_CR15","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann, M. D. et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093\u20132104 (2018).","journal-title":"N. Engl. J. Med."},{"key":"508_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nm.4051","volume":"22","author":"A Gros","year":"2016","unstructured":"Gros, A. et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat. Med. 22, 433\u2013438 (2016).","journal-title":"Nat. Med."},{"key":"508_CR17","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1126\/science.aaf2288","volume":"352","author":"E Stronen","year":"2016","unstructured":"Stronen, E. et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 352, 1337\u20131341 (2016).","journal-title":"Science"},{"key":"508_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10594-2","volume":"10","author":"AM D\u2019Alise","year":"2019","unstructured":"D\u2019Alise, A. M. et al. Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade. Nat. Commun. 10, 2688 (2019).","journal-title":"Nat. Commun."},{"key":"508_CR19","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","volume":"38","author":"V Leko","year":"2020","unstructured":"Leko, V. & Rosenberg, S. A. Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors. Cancer Cell 38, 454\u2013472 (2020).","journal-title":"Cancer Cell"},{"key":"508_CR20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41577-020-0390-6","volume":"21","author":"D Dersh","year":"2021","unstructured":"Dersh, D., Holly, J. & Yewdell, J. W. A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion. Nat. Rev. Immunol. 21, 116\u2013128 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"508_CR21","doi-asserted-by":"publisher","first-page":"12844","DOI":"10.18632\/aging.102557","volume":"11","author":"C von Kobbe","year":"2019","unstructured":"von Kobbe, C. Targeting senescent cells: approaches, opportunities, challenges. Aging 11, 12844\u201312861 (2019).","journal-title":"Aging"},{"key":"508_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cell.2020.11.034","volume":"184","author":"C Lopez-Otin","year":"2021","unstructured":"Lopez-Otin, C. & Kroemer, G. Hallmarks of health. Cell 184, 33\u201363 (2021).","journal-title":"Cell"},{"key":"508_CR23","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/nature03884","volume":"436","author":"S Gasser","year":"2005","unstructured":"Gasser, S., Orsulic, S., Brown, E. J. & Raulet, D. H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436, 1186\u20131190 (2005).","journal-title":"Nature"},{"key":"508_CR24","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature05529","volume":"445","author":"W Xue","year":"2007","unstructured":"Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656\u2013660 (2007).","journal-title":"Nature"},{"key":"508_CR25","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nri2604","volume":"9","author":"DH Raulet","year":"2009","unstructured":"Raulet, D. H. & Guerra, N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat. Rev. Immunol. 9, 568\u2013580 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"508_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","volume":"583","author":"C Amor","year":"2020","unstructured":"Amor, C. et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature 583, 127\u2013132 (2020).","journal-title":"Nature"},{"key":"508_CR27","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.cell.2016.01.049","volume":"164","author":"AK Palucka","year":"2016","unstructured":"Palucka, A. K. & Coussens, L. M. The basis of oncoimmunology. Cell 164, 1233\u20131247 (2016).","journal-title":"Cell"},{"key":"508_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97\u2013111 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"508_CR29","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1084\/jem.20050915","volume":"202","author":"N Casares","year":"2005","unstructured":"Casares, N. et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202, 1691\u20131701 (2005).","journal-title":"J. Exp. Med."},{"key":"508_CR30","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1126\/science.aad0779","volume":"350","author":"E Vacchelli","year":"2015","unstructured":"Vacchelli, E. et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science 350, 972\u2013978 (2015).","journal-title":"Science"},{"key":"508_CR31","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi, L., Humeau, J., Buque, A., Zitvogel, L. & Kroemer, G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol. 17, 725\u2013741 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"508_CR32","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191712","volume":"217","author":"MJ Frank","year":"2020","unstructured":"Frank, M. J. et al. Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I\/II trial. J. Exp. Med. 217, e20191712 (2020).","journal-title":"J. Exp. Med."},{"key":"508_CR33","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial, S. et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 21, 207\u2013221 (2020).","journal-title":"Lancet Oncol."},{"key":"508_CR34","doi-asserted-by":"publisher","first-page":"1795995","DOI":"10.1080\/2162402X.2020.1795995","volume":"9","author":"O Kepp","year":"2020","unstructured":"Kepp, O., Zitvogel, L. & Kroemer, G. Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer. Oncoimmunology 9, 1795995 (2020).","journal-title":"Oncoimmunology"},{"key":"508_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17644-0","volume":"11","author":"A Buque","year":"2020","unstructured":"Buque, A. et al. Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nat. Commun. 11, 3819 (2020).","journal-title":"Nat. Commun."},{"key":"508_CR36","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s41591-020-0882-8","volume":"26","author":"MP Roberti","year":"2020","unstructured":"Roberti, M. P. et al. Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. Nat. Med. 26, 919\u2013931 (2020).","journal-title":"Nat. Med."},{"key":"508_CR37","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.stem.2018.01.016","volume":"22","author":"NG Kooreman","year":"2018","unstructured":"Kooreman, N. G. et al. Autologous iPSC-based vaccines elicit anti-tumor responses in vivo. Cell Stem Cell 22, 501\u2013513.e7 (2018).","journal-title":"Cell Stem Cell"},{"key":"508_CR38","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1126\/science.aax0701","volume":"369","author":"A Fluckiger","year":"2020","unstructured":"Fluckiger, A. et al. Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage. Science 369, 936\u2013942 (2020).","journal-title":"Science"},{"key":"508_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1218106","volume":"5","author":"M Semeraro","year":"2016","unstructured":"Semeraro, M. et al. The ratio of CD8+\/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ. Oncoimmunology 5, e1218106 (2016).","journal-title":"Oncoimmunology"},{"key":"508_CR40","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1022301","volume":"4","author":"J Datta","year":"2015","unstructured":"Datta, J. et al. Progressive loss of anti-HER2 CD4+ T-helper type 1 response in breast tumorigenesis and the potential for immune restoration. Oncoimmunology 4, e1022301 (2015).","journal-title":"Oncoimmunology"},{"key":"508_CR41","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3389\/fphar.2016.00356","volume":"7","author":"NF Nocera","year":"2016","unstructured":"Nocera, N. F., Lee, M. C., De La Cruz, L. M., Rosemblit, C. & Czerniecki, B. J. Restoring lost anti-HER-2 Th1 immunity in breast cancer: a crucial role for Th1 cytokines in therapy and prevention. Front. Pharmacol. 7, 356 (2016).","journal-title":"Front. Pharmacol."},{"key":"508_CR42","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.1002\/cncr.26734","volume":"118","author":"A Sharma","year":"2012","unstructured":"Sharma, A. et al. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer 118, 4354\u20134362 (2012).","journal-title":"Cancer"},{"key":"508_CR43","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.2217\/imt-2016-0052","volume":"8","author":"LM De La Cruz","year":"2016","unstructured":"De La Cruz, L. M., Nocera, N. F. & Czerniecki, B. J. Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2\/neu-positive breast cancer: progress and potential. Immunotherapy 8, 1219\u20131232 (2016).","journal-title":"Immunotherapy"},{"key":"508_CR44","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41586-019-1330-0","volume":"571","author":"C Mascaux","year":"2019","unstructured":"Mascaux, C. et al. Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature 571, 570\u2013575 (2019).","journal-title":"Nature"},{"key":"508_CR45","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nri.2017.140","volume":"18","author":"OJ Finn","year":"2018","unstructured":"Finn, O. J. The dawn of vaccines for cancer prevention. Nat. Rev. Immunol. 18, 183\u2013194 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"508_CR46","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1158\/2326-6066.CIR-19-0870","volume":"8","author":"C Jacqueline","year":"2020","unstructured":"Jacqueline, C., Lee, A., Frey, N., Minden, J. S. & Finn, O. J. Inflammation-induced abnormal expression of self-molecules on epithelial cells: targets for tumor immunoprevention. Cancer Immunol. Res. 8, 1027\u20131038 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"508_CR47","doi-asserted-by":"publisher","first-page":"101394","DOI":"10.1016\/j.smim.2020.101394","volume":"47","author":"C Jacqueline","year":"2020","unstructured":"Jacqueline, C. & Finn, O. J. Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention. Semin. Immunol. 47, 101394 (2020).","journal-title":"Semin. Immunol."},{"key":"508_CR48","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1158\/2326-6066.CIR-19-0514","volume":"8","author":"M Kvorjak","year":"2020","unstructured":"Kvorjak, M. et al. Cross-talk between colon cells and macrophages increases ST6GALNAC1 and MUC1-sTn expression in ulcerative colitis and colitis-associated colon cancer. Cancer Immunol. Res. 8, 167\u2013178 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"508_CR49","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1084\/jem.20052494","volume":"203","author":"EA Reits","year":"2006","unstructured":"Reits, E. A. et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 203, 1259\u20131271 (2006).","journal-title":"J. Exp. Med."},{"key":"508_CR50","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1438107","volume":"7","author":"AM Gravett","year":"2018","unstructured":"Gravett, A. M., Trautwein, N., Stevanovic, S., Dalgleish, A. G. & Copier, J. Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells. Oncoimmunology 7, e1438107 (2018).","journal-title":"Oncoimmunology"},{"key":"508_CR51","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1158\/2326-6066.CIR-19-0056","volume":"7","author":"CY Oh","year":"2019","unstructured":"Oh, C. Y. et al. ALK and RET inhibitors promote HLA Class I antigen presentation and unmask new antigens within the tumor immunopeptidome. Cancer Immunol. Res. 7, 1984\u20131997 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"508_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16588-9","volume":"11","author":"LE Stopfer","year":"2020","unstructured":"Stopfer, L. E., Mesfin, J. M., Joughin, B. A., Lauffenburger, D. A. & White, F. M. Multiplexed relative and absolute quantitative immunopeptidomics reveals MHC I repertoire alterations induced by CDK4\/6 inhibition. Nat. Commun. 11, 2760 (2020).","journal-title":"Nat. Commun."},{"key":"508_CR53","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.immuni.2019.12.018","volume":"52","author":"J Galon","year":"2020","unstructured":"Galon, J. & Bruni, D. Tumor immunology and tumor evolution: intertwined histories. Immunity 52, 55\u201381 (2020).","journal-title":"Immunity"},{"key":"508_CR54","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1158\/2159-8290.CD-19-1366","volume":"10","author":"A Pennycuick","year":"2020","unstructured":"Pennycuick, A. et al. Immune surveillance in clinical regression of preinvasive squamous cell lung cancer. Cancer Discov. 10, 1489\u20131499 (2020).","journal-title":"Cancer Discov."},{"key":"508_CR55","first-page":"1153","volume":"8","author":"P Giacomini","year":"1988","unstructured":"Giacomini, P., Fisher, P. B., Duigou, G. J., Gambari, R. & Natali, P. G. Regulation of class II MHC gene expression by interferons: insights into the mechanism of action of interferon (review). Anticancer. Res. 8, 1153\u20131161 (1988).","journal-title":"Anticancer. Res."},{"key":"508_CR56","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3389\/fimmu.2017.00197","volume":"8","author":"E Muraro","year":"2017","unstructured":"Muraro, E. et al. Fighting viral infections and virus-driven tumors with cytotoxic CD4+ T cells. Front. Immunol. 8, 197 (2017).","journal-title":"Front. Immunol."},{"key":"508_CR57","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","volume":"181","author":"DY Oh","year":"2020","unstructured":"Oh, D. Y. et al. Intratumoral CD4+ T cells mediate anti-tumor cytotoxicity in human bladder cancer. Cell 181, 1612\u20131625.e13 (2020).","journal-title":"Cell"},{"key":"508_CR58","unstructured":"Gencode Gene. Release 37 (GRCh38.p13). Gencode Gene https:\/\/www.gencodegenes.org\/human (2020)."},{"key":"508_CR59","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrg3645","volume":"15","author":"NT Ingolia","year":"2014","unstructured":"Ingolia, N. T. Ribosome profiling: new views of translation, from single codons to genome scale. Nat. Rev. Genet. 15, 205\u2013213 (2014).","journal-title":"Nat. Rev. Genet."},{"key":"508_CR60","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1126\/science.aay0262","volume":"367","author":"J Chen","year":"2020","unstructured":"Chen, J. et al. Pervasive functional translation of noncanonical human open reading frames. Science 367, 1140\u20131146 (2020).","journal-title":"Science"},{"key":"508_CR61","first-page":"D403","volume":"47","author":"MA Brunet","year":"2019","unstructured":"Brunet, M. A. et al. OpenProt: a more comprehensive guide to explore eukaryotic coding potential and proteomes. Nucleic Acids Res. 47, D403\u2013D410 (2019).","journal-title":"Nucleic Acids Res."},{"key":"508_CR62","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.12.945840","author":"T Ouspenskaia","year":"2020","unstructured":"Ouspenskaia, T. et al. Thousands of novel unannotated proteins expand the MHC I immunopeptidome in cancer. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.02.12.945840 (2020).","journal-title":"bioRxiv"},{"key":"508_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00740-7","volume":"12","author":"JD Larouche","year":"2020","unstructured":"Larouche, J. D. et al. Widespread and tissue-specific expression of endogenous retroelements in human somatic tissues. Genome Med. 12, 40 (2020).","journal-title":"Genome Med."},{"key":"508_CR64","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2326-6066.CIR-19-0886","volume":"8","author":"F Erhard","year":"2020","unstructured":"Erhard, F., Dolken, L., Schilling, B. & Schlosser, A. Identification of the cryptic HLA-I immunopeptidome. Cancer Immunol. Res. 8, 1018\u20131026 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"508_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10238","volume":"7","author":"CM Laumont","year":"2016","unstructured":"Laumont, C. M. et al. Global proteogenomic analysis of human MHC class I-associated peptides derived from non-canonical reading frames. Nat. Commun. 7, 10238 (2016).","journal-title":"Nat. Commun."},{"key":"508_CR66","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5516","volume":"10","author":"CM Laumont","year":"2018","unstructured":"Laumont, C. M. et al. Non-coding regions are the main source of targetable tumor-specific antigens. Sci. Transl Med. 10, eaau5516 (2018).","journal-title":"Sci. Transl Med."},{"key":"508_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14968-9","volume":"11","author":"C Chong","year":"2020","unstructured":"Chong, C. et al. Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes. Nat. Commun. 11, 1293 (2020).","journal-title":"Nat. Commun."},{"key":"508_CR68","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/leu.2014.233","volume":"29","author":"C Berlin","year":"2015","unstructured":"Berlin, C. et al. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy. Leukemia 29, 647\u2013659 (2015).","journal-title":"Leukemia"},{"key":"508_CR69","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1182\/blood-2018-07-866830","volume":"133","author":"T Bilich","year":"2019","unstructured":"Bilich, T. et al. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. Blood 133, 550\u2013565 (2019).","journal-title":"Blood"},{"key":"508_CR70","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1316438","volume":"7","author":"A Nelde","year":"2018","unstructured":"Nelde, A. et al. HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy. Oncoimmunology 7, e1316438 (2018).","journal-title":"Oncoimmunology"},{"key":"508_CR71","doi-asserted-by":"publisher","first-page":"D1237","DOI":"10.1093\/nar\/gkx664","volume":"46","author":"W Shao","year":"2018","unstructured":"Shao, W. et al. The SysteMHC Atlas project. Nucleic Acids Res. 46, D1237\u2013D1247 (2018).","journal-title":"Nucleic Acids Res."},{"key":"508_CR72","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201700251","volume":"18","author":"J Lanoix","year":"2018","unstructured":"Lanoix, J. et al. Comparison of the MHC I immunopeptidome repertoir of B-cell lymphoblasts using two isolation methods. Proteomics 18, e1700251 (2018).","journal-title":"Proteomics"},{"key":"508_CR73","doi-asserted-by":"publisher","first-page":"9194","DOI":"10.1021\/acs.analchem.0c01545","volume":"92","author":"S Pfammatter","year":"2020","unstructured":"Pfammatter, S. et al. Extending the comprehensiveness of immunopeptidome analyses using isobaric peptide labeling. Anal. Chem. 92, 9194\u20139204 (2020).","journal-title":"Anal. Chem."},{"key":"508_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-018-0354-x","volume":"11","author":"S Boegel","year":"2018","unstructured":"Boegel, S. et al. HLA and proteasome expression body map. BMC Med. Genomics 11, 36 (2018).","journal-title":"BMC Med. Genomics"},{"key":"508_CR75","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.4049\/jimmunol.2000225","volume":"205","author":"M Benhammadi","year":"2020","unstructured":"Benhammadi, M. et al. IFN lambda enhances constitutive expression of MHC class I molecules on thymic epithelial cells. J. Immunol. 205, 1268\u20131280 (2020).","journal-title":"J. Immunol."},{"key":"508_CR76","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/ni.3314","volume":"17","author":"JL Hukelmann","year":"2016","unstructured":"Hukelmann, J. L. et al. The cytotoxic T cell proteome and its shaping by the kinase mTOR. Nat. Immunol. 17, 104\u2013112 (2016).","journal-title":"Nat. Immunol."},{"key":"508_CR77","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/msb.2011.81","volume":"7","author":"N Nagaraj","year":"2011","unstructured":"Nagaraj, N. et al. Deep proteome and transcriptome mapping of a human cancer cell line. Mol. Syst. Biol. 7, 548 (2011).","journal-title":"Mol. Syst. Biol."},{"key":"508_CR78","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1172\/JCI88590","volume":"126","author":"H Pearson","year":"2016","unstructured":"Pearson, H. et al. MHC class I-associated peptides derive from selective regions of the human genome. J. Clin. Invest. 126, 4690\u20134701 (2016).","journal-title":"J. Clin. Invest."},{"key":"508_CR79","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.3389\/fimmu.2017.01367","volume":"8","author":"M Muller","year":"2017","unstructured":"Muller, M., Gfeller, D., Coukos, G. & Bassani-Sternberg, M. \u2018Hotspots\u2019 of antigen presentation revealed by human leukocyte antigen ligandomics for neoantigen prioritization. Front. Immunol. 8, 1367 (2017).","journal-title":"Front. Immunol."},{"key":"508_CR80","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/msb.2011.68","volume":"7","author":"E Caron","year":"2011","unstructured":"Caron, E. et al. The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation. Mol. Syst. Biol. 7, 533 (2011).","journal-title":"Mol. Syst. Biol."},{"key":"508_CR81","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.coi.2020.05.009","volume":"64","author":"JW Yewdell","year":"2020","unstructured":"Yewdell, J. W. & Holly, J. DRiPs get molecular. Curr. Opin. Immunol. 64, 130\u2013136 (2020).","journal-title":"Curr. Opin. Immunol."},{"key":"508_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19142-9","volume":"11","author":"LC Demmers","year":"2020","unstructured":"Demmers, L. C. et al. Single-cell derived tumor organoids display diversity in HLA class I peptide presentation. Nat. Commun. 11, 5338 (2020).","journal-title":"Nat. Commun."},{"key":"508_CR83","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution.Cell 171, 1259\u20131271.e11 (2017).","journal-title":"Cell"},{"key":"508_CR84","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-3-030-17864-2_2","volume":"1151","author":"F Garrido","year":"2019","unstructured":"Garrido, F. MHC\/HLA class I loss in cancer cells. Adv. Exp. Med. Biol. 1151, 15\u201378 (2019).","journal-title":"Adv. Exp. Med. Biol."},{"key":"508_CR85","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.immuni.2020.11.002","volume":"54","author":"D Dersh","year":"2021","unstructured":"Dersh, D. et al. Genome-wide screens identify lineage- and tumor-specific genes modulating MHC-I- and MHC-II-restricted immunosurveillance of human lymphomas. Immunity 54, 116\u2013131.e10 (2021).","journal-title":"Immunity"},{"key":"508_CR86","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/nm1311","volume":"11","author":"MC Meunier","year":"2005","unstructured":"Meunier, M. C. et al. T cells targeted against a single minor histocompatibility antigen can cure solid tumors. Nat. Med. 11, 1222\u20131229 (2005).","journal-title":"Nat. Med."},{"key":"508_CR87","doi-asserted-by":"publisher","first-page":"409","DOI":"10.4161\/onci.18851","volume":"1","author":"P Kvistborg","year":"2012","unstructured":"Kvistborg, P. et al. TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology 1, 409\u2013418 (2012).","journal-title":"Oncoimmunology"},{"key":"508_CR88","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41591-018-0266-5","volume":"25","author":"W Scheper","year":"2019","unstructured":"Scheper, W. et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat. Med. 25, 89\u201394 (2019).","journal-title":"Nat. Med."},{"key":"508_CR89","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","volume":"557","author":"Y Simoni","year":"2018","unstructured":"Simoni, Y. et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575\u2013579 (2018).","journal-title":"Nature"},{"key":"508_CR90","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrc3670","volume":"14","author":"PG Coulie","year":"2014","unstructured":"Coulie, P. G., van den Eynde, B. J., van der Bruggen, P. & Boon, T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat. Rev. Cancer 14, 135\u2013146 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"508_CR91","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/ni.3682","volume":"18","author":"E Tran","year":"2017","unstructured":"Tran, E., Robbins, P. F. & Rosenberg, S. A. \u2018Final common pathway\u2019 of human cancer immunotherapy: targeting random somatic mutations. Nat. Immunol. 18, 255\u2013262 (2017).","journal-title":"Nat. Immunol."},{"key":"508_CR92","doi-asserted-by":"crossref","unstructured":"Apavaloaei, A., Hardy, M. P., Thibault, P. & Perreault, C. The origin and immune recognition of tumor-specific antigens. Cancers 12, 2607 (2020).","DOI":"10.3390\/cancers12092607"},{"key":"508_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-019-0636-8","volume":"11","author":"MW L\u00f6ffler","year":"2019","unstructured":"L\u00f6ffler, M. W. et al. Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma. Genome Med. 11, 1\u201316 (2019).","journal-title":"Genome Med."},{"key":"508_CR94","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1038\/s41588-019-0532-6","volume":"51","author":"J Van den Eynden","year":"2019","unstructured":"Van den Eynden, J., Jimenez-Sanchez, A., Miller, M. L. & Larsson, E. Lack of detectable neoantigen depletion signals in the untreated cancer genome. Nat. Genet. 51, 1741\u20131748 (2019).","journal-title":"Nat. Genet."},{"key":"508_CR95","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.53244","volume":"9","author":"K Murata","year":"2020","unstructured":"Murata, K. et al. Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma. eLife 9, e53244 (2020).","journal-title":"eLife"},{"key":"508_CR96","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1158\/2326-6066.CIR-19-0541","volume":"8","author":"Q Zhao","year":"2020","unstructured":"Zhao, Q. et al. Proteogenomics uncovers a vast repertoire of shared tumor-specific antigens in ovarian cancer. Cancer Immunol. Res. 8, 544\u2013555 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"508_CR97","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1511506","volume":"7","author":"L Bezu","year":"2018","unstructured":"Bezu, L. et al. Trial watch: Peptide-based vaccines in anticancer therapy. Oncoimmunology 7, e1511506 (2018).","journal-title":"Oncoimmunology"},{"key":"508_CR98","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41571-020-0387-x","volume":"17","author":"SP Haen","year":"2020","unstructured":"Haen, S. P., Loffler, M. W., Rammensee, H. G. & Brossart, P. Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nat. Rev. Clin. Oncol. 17, 595\u2013610 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"508_CR99","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1074\/mcp.M600310-MCP200","volume":"6","author":"AO Weinzierl","year":"2007","unstructured":"Weinzierl, A. O. et al. Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol. Cell Proteom. 6, 102\u2013113 (2007).","journal-title":"Mol. Cell Proteom."},{"key":"508_CR100","doi-asserted-by":"publisher","first-page":"12703","DOI":"10.1073\/pnas.96.22.12703","volume":"96","author":"C Kurts","year":"1999","unstructured":"Kurts, C. et al. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc. Natl Acad. Sci. USA 96, 12703\u201312707 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"508_CR101","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.immuni.2015.05.001","volume":"42","author":"W Yu","year":"2015","unstructured":"Yu, W. et al. Clonal deletion prunes but does not eliminate self-specific alphabeta CD8+ T lymphocytes. Immunity 42, 929\u2013941 (2015).","journal-title":"Immunity"},{"key":"508_CR102","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.it.2015.12.005","volume":"37","author":"DM Richards","year":"2016","unstructured":"Richards, D. M., Kyewski, B. & Feuerer, M. Re-examining the nature and function of self-reactive T cells. Trends Immunol. 37, 114\u2013125 (2016).","journal-title":"Trends Immunol."},{"key":"508_CR103","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1073\/pnas.95.9.5235","volume":"95","author":"JR Delaney","year":"1998","unstructured":"Delaney, J. R., Sykulev, Y., Eisen, H. N. & Tonegawa, S. Differences in the level of expression of class I major histocompatibility complex proteins on thymic epithelial and dendritic cells influence the decision of immature thymocytes between positive and negative selection. Proc. Natl Acad. Sci. USA 95, 5235\u20135240 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"508_CR104","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/ni.3327","volume":"17","author":"D Malhotra","year":"2016","unstructured":"Malhotra, D. et al. Tolerance is established in polyclonal CD4+ T cells by distinct mechanisms, according to self-peptide expression patterns. Nat. Immunol. 17, 187\u2013195 (2016).","journal-title":"Nat. Immunol."},{"key":"508_CR105","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aao4013","volume":"3","author":"S Culina","year":"2018","unstructured":"Culina, S. et al. Islet-reactive CD8+ T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors. Sci. Immunol. 3, eaao4013 (2018).","journal-title":"Sci. Immunol."},{"key":"508_CR106","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nri3667","volume":"14","author":"L Klein","year":"2014","unstructured":"Klein, L., Kyewski, B., Allen, P. M. & Hogquist, K. A. Positive and negative selection of the T cell repertoire: what thymocytes see (and don\u2019t see). Nat. Rev. Immunol. 14, 377\u2013391 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"508_CR107","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1158\/0008-5472.CAN-06-2112","volume":"67","author":"S Cloosen","year":"2007","unstructured":"Cloosen, S. et al. Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: implications for self-tolerance and tumor therapy. Cancer Res. 67, 3919\u20133926 (2007).","journal-title":"Cancer Res."},{"key":"508_CR108","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","volume":"183","author":"DK Wells","year":"2020","unstructured":"Wells, D. K. et al. Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell 183, 818\u2013834 (2020).","journal-title":"Cell"},{"key":"508_CR109","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41586-020-2424-4","volume":"583","author":"T Krausgruber","year":"2020","unstructured":"Krausgruber, T. et al. Structural cells are key regulators of organ-specific immune responses. Nature 583, 296\u2013302 (2020).","journal-title":"Nature"},{"key":"508_CR110","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","volume":"17","author":"K Esfahani","year":"2020","unstructured":"Esfahani, K. et al. Moving towards personalized treatments of immune-related adverse events. Nat. Rev. Clin. Oncol. 17, 504\u2013515 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"508_CR111","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1073\/pnas.96.6.2982","volume":"96","author":"WW Overwijk","year":"1999","unstructured":"Overwijk, W. W. et al. Vaccination with a recombinant vaccinia virus encoding a \u201cself\u201d antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4+ T lymphocytes. Proc. Natl Acad. Sci. USA 96, 2982\u20132987 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"508_CR112","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<89::AID-IJC14>3.0.CO;2-I","volume":"86","author":"J Steitz","year":"2000","unstructured":"Steitz, J. et al. Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma. Int. J. Cancer 86, 89\u201394 (2000).","journal-title":"Int. J. Cancer"},{"key":"508_CR113","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aam6346","volume":"2","author":"BT Malik","year":"2017","unstructured":"Malik, B. T. et al. Resident memory T cells in the skin mediate durable immunity to melanoma. Sci. Immunol. 2, eaam6346 (2017).","journal-title":"Sci. Immunol."},{"key":"508_CR114","first-page":"218","volume":"15","author":"TM Gonzalez Santiago","year":"2017","unstructured":"Gonzalez Santiago, T. M., Wetter, D. A., Lowe, G. C. & Sciallis, G. F. Generalized discoid lupus erythematosus as the presenting sign of small cell lung carcinoma. Skinmed 15, 218\u2013220 (2017).","journal-title":"Skinmed"},{"key":"508_CR115","first-page":"292","volume":"108","author":"Y Gonzalez Amores","year":"2016","unstructured":"Gonzalez Amores, Y., Hernando Rebollar, S. & Casado Bernabeu, A. Lupus as a paraneoplastic manifestation of cholangiocarcinoma. Rev. Esp. Enferm. Dig. 108, 292 (2016).","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"508_CR116","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.3389\/fimmu.2018.03112","volume":"9","author":"ATJ Maria","year":"2018","unstructured":"Maria, A. T. J. et al. Intriguing relationships between cancer and systemic sclerosis: role of the immune system and other contributors. Front. Immunol. 9, 3112 (2018).","journal-title":"Front. Immunol."},{"key":"508_CR117","first-page":"1073","volume":"22","author":"I Zerdes","year":"2017","unstructured":"Zerdes, I. et al. How can we effectively address the paraneoplastic dermatomyositis: diagnosis, risk factors and treatment options. J. BUON 22, 1073\u20131080 (2017).","journal-title":"J. BUON"},{"key":"508_CR118","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","volume":"16","author":"F Graus","year":"2019","unstructured":"Graus, F. & Dalmau, J. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 16, 535\u2013548 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"508_CR119","doi-asserted-by":"publisher","first-page":"6253","DOI":"10.21037\/jtd.2020.03.88","volume":"12","author":"Z Soomro","year":"2020","unstructured":"Soomro, Z. et al. Paraneoplastic syndromes in small cell lung cancer. J. Thorac. Dis. 12, 6253\u20136263 (2020).","journal-title":"J. Thorac. Dis."},{"key":"508_CR120","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3390\/biomedicines8110490","volume":"8","author":"J Przezdziecka-Dolyk","year":"2020","unstructured":"Przezdziecka-Dolyk, J. et al. Ocular paraneoplastic syndromes. Biomedicines 8, 490 (2020).","journal-title":"Biomedicines"},{"key":"508_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73131-y","volume":"10","author":"L Cao","year":"2020","unstructured":"Cao, L. et al. Chronic lymphocytic leukemia-associated paraneoplastic pemphigus: potential cause and therapeutic strategies. Sci. Rep. 10, 16357 (2020).","journal-title":"Sci. Rep."},{"key":"508_CR122","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.2169\/internalmedicine.2210-18","volume":"58","author":"A Okamoto","year":"2019","unstructured":"Okamoto, A., Watanabe, T., Kamata, K., Minaga, K. & Kudo, M. Recent updates on the relationship between cancer and autoimmune pancreatitis. Intern. Med. 58, 1533\u20131539 (2019).","journal-title":"Intern. Med."},{"key":"508_CR123","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/pin.12768","volume":"69","author":"T Sugiyama","year":"2019","unstructured":"Sugiyama, T. et al. A case of high-grade pancreatic intraepithelial neoplasia concomitant with type 1 autoimmune pancreatitis: The process underlying both conditions. Pathol. Int. 69, 165\u2013171 (2019).","journal-title":"Pathol. Int."},{"key":"508_CR124","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/3315","volume":"4","author":"ML Albert","year":"1998","unstructured":"Albert, M. L. et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat. Med. 4, 1321\u20131324 (1998).","journal-title":"Nat. Med."},{"key":"508_CR125","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nrneurol.2017.144","volume":"13","author":"LM Yshii","year":"2017","unstructured":"Yshii, L. M., Hohlfeld, R. & Liblau, R. S. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat. Rev. Neurol. 13, 755\u2013763 (2017).","journal-title":"Nat. Rev. Neurol."},{"key":"508_CR126","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000604","volume":"6","author":"A Vogrig","year":"2019","unstructured":"Vogrig, A. et al. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. Neurol. Neuroimmunol. Neuroinflamm. 6, e604 (2019).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"508_CR127","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"508_CR128","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4022-5","volume":"18","author":"RL Evans","year":"2018","unstructured":"Evans, R. L., Pottala, J. V., Nagata, S. & Egland, K. A. Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality. BMC Cancer 18, 119 (2018).","journal-title":"BMC Cancer"},{"key":"508_CR129","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1452582","volume":"7","author":"S Wang","year":"2018","unstructured":"Wang, S. et al. Using a panel of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of gastric cancer. Oncoimmunology 7, e1452582 (2018).","journal-title":"Oncoimmunology"},{"key":"508_CR130","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s00262-018-2135-y","volume":"67","author":"JA Koziol","year":"2018","unstructured":"Koziol, J. A., Imai, H., Dai, L., Zhang, J. Y. & Tan, E. M. Early detection of hepatocellular carcinoma using autoantibody profiles from a panel of tumor-associated antigens. Cancer Immunol. Immunother. 67, 835\u2013841 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"508_CR131","doi-asserted-by":"publisher","first-page":"101042831771166","DOI":"10.1177\/1010428317711662","volume":"39","author":"P Li","year":"2017","unstructured":"Li, P. et al. Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer. Tumour Biol. 39, 1010428317711662 (2017).","journal-title":"Tumour Biol."},{"key":"508_CR132","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1428157","volume":"7","author":"J Michels","year":"2018","unstructured":"Michels, J. et al. Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial. Oncoimmunology 7, e1428157 (2018).","journal-title":"Oncoimmunology"},{"key":"508_CR133","doi-asserted-by":"publisher","first-page":"101042831769913","DOI":"10.1177\/1010428317699132","volume":"39","author":"H Sun","year":"2017","unstructured":"Sun, H. et al. Serum autoantibodies against a panel of 15 tumor-associated antigens in the detection of ovarian cancer. Tumour Biol. 39, 1010428317699132 (2017).","journal-title":"Tumour Biol."},{"key":"508_CR134","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.1200\/JCO.2007.15.0284","volume":"26","author":"MC Dieu-Nosjean","year":"2008","unstructured":"Dieu-Nosjean, M. C. et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 26, 4410\u20134417 (2008).","journal-title":"J. Clin. Oncol."},{"key":"508_CR135","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Sautes-Fridman","year":"2019","unstructured":"Sautes-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307\u2013325 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"508_CR136","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.3389\/fimmu.2019.01884","volume":"10","author":"A Maoz","year":"2019","unstructured":"Maoz, A., Dennis, M. & Greenson, J. K. The Crohn\u2019s-like lymphoid reaction to colorectal cancer-tertiary lymphoid structures with immunologic and potentially therapeutic relevance in colorectal cancer. Front. Immunol. 10, 1884 (2019).","journal-title":"Front. Immunol."},{"key":"508_CR137","doi-asserted-by":"publisher","first-page":"128","DOI":"10.31768\/2312-8852.2018.40(2):128-131","volume":"40","author":"TM Myshunina","year":"2018","unstructured":"Myshunina, T. M., Guda, B. D., Bolgov, M. Y., Mikhailenko, N. I. & Tronko, N. D. Differentiated thyroid carcinomas associated with chronic thyroiditis: biological and clinical properties. Exp. Oncol. 40, 128\u2013131 (2018).","journal-title":"Exp. Oncol."},{"key":"508_CR138","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3803\/EnM.2018.33.4.473","volume":"33","author":"S Moon","year":"2018","unstructured":"Moon, S. et al. Associations between Hashimoto thyroiditis and clinical outcomes of papillary thyroid cancer: a meta-analysis of observational studies. Endocrinol. Metab. 33, 473\u2013484 (2018).","journal-title":"Endocrinol. Metab."},{"key":"508_CR139","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143558","volume":"10","author":"P Gozzard","year":"2015","unstructured":"Gozzard, P., Chapman, C., Vincent, A., Lang, B. & Maddison, P. Novel humoral prognostic markers in small-cell lung carcinoma: a prospective study. PLoS ONE 10, e0143558 (2015).","journal-title":"PLoS ONE"},{"key":"508_CR140","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1212\/WNL.0000000000003794","volume":"88","author":"P Maddison","year":"2017","unstructured":"Maddison, P., Gozzard, P., Grainge, M. J. & Lang, B. Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 88, 1334\u20131339 (2017).","journal-title":"Neurology"},{"key":"508_CR141","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/CMR.0000000000000573","volume":"29","author":"IG Motofei","year":"2019","unstructured":"Motofei, I. G. Melanoma and autoimmunity: spontaneous regressions as a possible model for new therapeutic approaches. Melanoma Res. 29, 231\u2013236 (2019).","journal-title":"Melanoma Res."},{"key":"508_CR142","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jaad.2014.07.050","volume":"71","author":"A Paradisi","year":"2014","unstructured":"Paradisi, A. et al. Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo. J. Am. Acad. Dermatol. 71, 1110\u20131116 (2014).","journal-title":"J. Am. Acad. Dermatol."},{"key":"508_CR143","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1200\/JCO.18.01223","volume":"37","author":"JM Bae","year":"2019","unstructured":"Bae, J. M. et al. Markedly reduced risk of internal malignancies in patients with vitiligo: a nationwide population-based cohort study. J. Clin. Oncol. 37, 903\u2013911 (2019).","journal-title":"J. Clin. Oncol."},{"key":"508_CR144","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","volume":"33","author":"HE Teulings","year":"2015","unstructured":"Teulings, H. E. et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J. Clin. Oncol. 33, 773\u2013781 (2015).","journal-title":"J. Clin. Oncol."},{"key":"508_CR145","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01549-2","volume":"18","author":"X Zhou","year":"2020","unstructured":"Zhou, X. et al. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 18, 87 (2020).","journal-title":"BMC Med."},{"key":"508_CR146","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","volume":"15","author":"R De Angelis","year":"2014","unstructured":"De Angelis, R. et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE\u20135-a population-based study. Lancet Oncol. 15, 23\u201334 (2014).","journal-title":"Lancet Oncol."},{"key":"508_CR147","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2159-8290.CD-20-0672","volume":"11","author":"M Montesion","year":"2021","unstructured":"Montesion, M. et al. Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response. Cancer Discov. 11, 282\u2013292 (2021).","journal-title":"Cancer Discov."},{"key":"508_CR148","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1001\/jamadermatol.2017.1679","volume":"153","author":"Y Nakamura","year":"2017","unstructured":"Nakamura, Y. et al. Nivolumab therapy for treatment-related vitiligo in a patient with relapsed metastatic melanoma. JAMA Dermatol. 153, 942\u2013944 (2017).","journal-title":"JAMA Dermatol."},{"key":"508_CR149","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2340\/00015555-3199","volume":"99","author":"C Nardin","year":"2019","unstructured":"Nardin, C., Pelletier, F., Puzenat, E. & Aubin, F. Vitiligo repigmentation with melanoma progression during pembrolizumab treatment. Acta Derm. Venereol. 99, 913\u2013914 (2019).","journal-title":"Acta Derm. Venereol."},{"key":"508_CR150","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40264-019-00875-6","volume":"43","author":"S Babai","year":"2020","unstructured":"Babai, S., Voisin, A. L., Bertin, C., Gouverneur, A. & Le-Louet, H. Occurrences and outcomes of immune checkpoint inhibitors-induced vitiligo in cancer patients: a retrospective cohort study. Drug. Saf. 43, 111\u2013117 (2020).","journal-title":"Drug. Saf."},{"key":"508_CR151","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jtho.2018.11.016","volume":"14","author":"K Suresh","year":"2019","unstructured":"Suresh, K. et al. Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy. J. Thorac. Oncol. 14, 494\u2013502 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"508_CR152","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cllc.2019.07.006","volume":"20","author":"J Fukihara","year":"2019","unstructured":"Fukihara, J. et al. Prognostic Impact and risk factors of immune-related pneumonitis in patients with non-small-cell lung cancer who received programmed death 1 inhibitors. Clin. Lung Cancer 20, 442\u2013450.e4 (2019).","journal-title":"Clin. Lung Cancer"},{"key":"508_CR153","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1177\/1078155219829813","volume":"25","author":"M Lei","year":"2019","unstructured":"Lei, M., Michael, A., Patel, S. & Wang, D. Evaluation of the impact of thyroiditis development in patients receiving immunotherapy with programmed cell death-1 inhibitors. J. Oncol. Pharm. Pract. 25, 1402\u20131411 (2019).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"508_CR154","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001198","volume":"8","author":"V Patel","year":"2020","unstructured":"Patel, V. et al. Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma. J. Immunother. Cancer 8, e001198 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"508_CR155","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nbt.4313","volume":"37","author":"B Bulik-Sullivan","year":"2019","unstructured":"Bulik-Sullivan, B. et al. Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. Nat. Biotechnol. 37, 55\u201363 (2019).","journal-title":"Nat. Biotechnol."},{"key":"508_CR156","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4049\/jimmunol.177.1.227","volume":"177","author":"SB Qian","year":"2006","unstructured":"Qian, S. B. et al. Tight linkage between translation and MHC class I peptide ligand generation implies specialized antigen processing for defective ribosomal products. J. Immunol. 177, 227\u2013233 (2006).","journal-title":"J. Immunol."},{"key":"508_CR157","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.immuni.2017.02.007","volume":"46","author":"JG Abelin","year":"2017","unstructured":"Abelin, J. G. et al. Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction. Immunity 46, 315\u2013326 (2017).","journal-title":"Immunity"},{"key":"508_CR158","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1093\/nar\/gky1296","volume":"47","author":"RP Martins","year":"2019","unstructured":"Martins, R. P. et al. Nuclear processing of nascent transcripts determines synthesis of full-length proteins and antigenic peptides. Nucleic Acids Res. 47, 3086\u20133100 (2019).","journal-title":"Nucleic Acids Res."},{"key":"508_CR159","doi-asserted-by":"publisher","first-page":"17951","DOI":"10.1073\/pnas.1309956110","volume":"110","author":"S Apcher","year":"2013","unstructured":"Apcher, S. et al. Translation of pre-spliced RNAs in the nuclear compartment generates peptides for the MHC class I pathway. Proc. Natl Acad. Sci. USA 110, 17951\u201317956 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"508_CR160","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.molcel.2018.12.020","volume":"73","author":"J Wei","year":"2019","unstructured":"Wei, J. et al. Ribosomal proteins regulate MHC class I peptide generation for immunosurveillance. Mol. Cell 73, 1162\u20131173.e5 (2019).","journal-title":"Mol. Cell"},{"key":"508_CR161","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.tcb.2019.09.004","volume":"29","author":"JW Yewdell","year":"2019","unstructured":"Yewdell, J. W., Dersh, D. & Fahraeus, R. Peptide channeling: the key to MHC class I immunosurveillance? Trends Cell Biol. 29, 929\u2013939 (2019).","journal-title":"Trends Cell Biol."},{"key":"508_CR162","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.4049\/jimmunol.1602122","volume":"198","author":"J Wei","year":"2017","unstructured":"Wei, J. et al. Varied role of ubiquitylation in generating MHC class i peptide ligands. J. Immunol. 198, 3835\u20133845 (2017).","journal-title":"J. Immunol."},{"key":"508_CR163","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1074\/mcp.M114.042812","volume":"14","author":"M Bassani-Sternberg","year":"2015","unstructured":"Bassani-Sternberg, M., Pletscher-Frankild, S., Jensen, L. J. & Mann, M. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol. Cell Proteom. 14, 658\u2013673 (2015).","journal-title":"Mol. Cell Proteom."},{"key":"508_CR164","doi-asserted-by":"publisher","first-page":"100032","DOI":"10.1074\/mcp.RA120.002201","volume":"20","author":"G Forlani","year":"2020","unstructured":"Forlani, G. et al. CIITA-transduced glioblastoma cells uncover a rich repertoire of clinically relevant tumor-associated HLA-II antigens. Mol. Cell Proteomics 20, 100032 (2020).","journal-title":"Mol. Cell Proteomics"},{"key":"508_CR165","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1074\/mcp.M900566-MCP200","volume":"9","author":"D de Verteuil","year":"2010","unstructured":"de Verteuil, D. et al. Deletion of immunoproteasome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules. Mol. Cell Proteom. 9, 2034\u20132047 (2010).","journal-title":"Mol. Cell Proteom."},{"key":"508_CR166","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.coi.2011.12.002","volume":"24","author":"N Vigneron","year":"2012","unstructured":"Vigneron, N. & Van den Eynde, B. J. Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity. Curr. Opin. Immunol. 24, 84\u201391 (2012).","journal-title":"Curr. Opin. Immunol."},{"key":"508_CR167","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2172-10-10","volume":"10","author":"DP Granados","year":"2009","unstructured":"Granados, D. P. et al. ER stress affects processing of MHC class I-associated peptides. BMC Immunol. 10, 10 (2009).","journal-title":"BMC Immunol."},{"key":"508_CR168","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.humimm.2009.08.012","volume":"71","author":"A Wahl","year":"2010","unstructured":"Wahl, A., Schafer, F., Bardet, W. & Hildebrand, W. H. HLA class I molecules reflect an altered host proteome after influenza virus infection. Hum. Immunol. 71, 14\u201322 (2010).","journal-title":"Hum. Immunol."},{"key":"508_CR169","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1158\/1078-0432.CCR-19-0596","volume":"25","author":"AM Jaeger","year":"2019","unstructured":"Jaeger, A. M. et al. Rebalancing protein homeostasis enhances tumor antigen presentation. Clin. Cancer Res. 25, 6392\u20136405 (2019).","journal-title":"Clin. Cancer Res."},{"key":"508_CR170","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/imr.12582","volume":"280","author":"N Bloy","year":"2017","unstructured":"Bloy, N. et al. Immunogenic stress and death of cancer cells: contribution of antigenicity vs adjuvanticity to immunosurveillance. Immunol. Rev. 280, 165\u2013174 (2017).","journal-title":"Immunol. Rev."},{"key":"508_CR171","doi-asserted-by":"publisher","first-page":"djw027","DOI":"10.1093\/jnci\/djw027","volume":"108","author":"LS Rozek","year":"2016","unstructured":"Rozek, L. S. et al. Tumor-infiltrating lymphocytes, Crohn\u2019s-like lymphoid reaction, and survival from colorectal cancer. J. Natl Cancer Inst. 108, djw027 (2016).","journal-title":"J. Natl Cancer Inst."},{"key":"508_CR172","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/annonc\/mdp325","volume":"21","author":"P Quaglino","year":"2010","unstructured":"Quaglino, P. et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann. Oncol. 21, 409\u2013414 (2010).","journal-title":"Ann. Oncol."},{"key":"508_CR173","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","volume":"18","author":"S Turajlic","year":"2017","unstructured":"Turajlic, S. et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 18, 1009\u20131021 (2017).","journal-title":"Lancet Oncol."},{"key":"508_CR174","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.molcel.2019.11.004","volume":"77","author":"P Liu","year":"2020","unstructured":"Liu, P. et al. Immunosuppression by mutated calreticulin released from malignant cells. Mol. Cell 77, 748\u2013760.e9 (2020).","journal-title":"Mol. Cell"},{"key":"508_CR175","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5516","volume":"10","author":"CM Laumont","year":"2018","unstructured":"Laumont, C. M. et al. Noncoding regions are the main source of targetable tumor-specific antigens. Sci. Transl Med. 10, eaau5516 (2018).","journal-title":"Sci. Transl Med."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-021-00508-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-021-00508-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-021-00508-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T13:20:39Z","timestamp":1684848039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-021-00508-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":175,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["508"],"URL":"https:\/\/doi.org\/10.1038\/s41571-021-00508-x","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,11]]},"assertion":[{"value":"26 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.Z. and G.K. are founders of EverImmune. G.K. is a founder of Samsara Therapeutics and Therafast Bio. O.J.F. is a consultant for Biovelocita, GeoVax, Immodulon, Iaso Therapeutics and PDS Biotech. C.P. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}